Ophthalmic care company NuSight Medical has introduced a new medical device called the NuLids System to treat dry eyes.

Unveiled at the American Optometric Association meeting in Denver, NuLids is said to improve dry eye conditions by gently stimulating and rejuvenating the Meibomian glands in the eye.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NuSight Medical president and CEO Rob Foster said: “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice.

“The company stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.”

“And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”

NuSight Medical founder and chairman John Olkowski said that nearly 86% of dry eye patients’ Meibomian gland function are damaged leading to unstable tear film and its premature breakdown.

The NuLids facilitates the production and flow of meibum at the gland reducing signs of dry eye.

At a clinical study, the NuLids System bettered Tear Breakup Time by 65%, while Meibomian Glands Yielding Liquid Secretions improved by 81%.

Most of the patients in the study also reported significant improvement in their dry eye conditions following two weeks of daily usage.

Taking around one minute per day, the NuLids process can be carried out with the in-office procedures performed by eye doctors.

NuSight claimed that the NuLids system is convenient to use without any known side effects.

The company also stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.